Oppenheimer Asset Management Inc. lowered its position in shares of CVS Health Corp (NYSE:CVS) by 24.2% during the third quarter, Holdings Channel reports. The fund owned 25,367 shares of the pharmacy operator’s stock after selling 8,098 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in CVS Health were worth $2,064,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Horan Capital Advisors LLC. boosted its position in CVS Health by 3.2% during the second quarter. Horan Capital Advisors LLC. now owns 32,115 shares of the pharmacy operator’s stock valued at $2,584,000 after acquiring an additional 1,000 shares during the last quarter. Community Bank N.A. boosted its position in CVS Health by 7.3% during the second quarter. Community Bank N.A. now owns 19,976 shares of the pharmacy operator’s stock valued at $1,608,000 after acquiring an additional 1,362 shares during the last quarter. FIL Ltd boosted its position in CVS Health by 13.8% during the second quarter. FIL Ltd now owns 514,836 shares of the pharmacy operator’s stock valued at $41,424,000 after acquiring an additional 62,318 shares during the last quarter. Midwest Investment Management LLC boosted its position in CVS Health by 6.2% during the second quarter. Midwest Investment Management LLC now owns 21,382 shares of the pharmacy operator’s stock valued at $1,720,000 after acquiring an additional 1,245 shares during the last quarter. Finally, ETRADE Capital Management LLC boosted its position in CVS Health by 3.7% during the second quarter. ETRADE Capital Management LLC now owns 55,653 shares of the pharmacy operator’s stock valued at $4,478,000 after acquiring an additional 1,979 shares during the last quarter. 81.69% of the stock is currently owned by institutional investors and hedge funds.

Shares of CVS Health Corp (CVS) opened at $74.35 on Thursday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55. CVS Health Corp has a fifty-two week low of $66.45 and a fifty-two week high of $84.00. The firm has a market cap of $74,981.66, a PE ratio of 15.36, a P/E/G ratio of 1.24 and a beta of 0.93.

CVS Health (NYSE:CVS) last posted its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The company had revenue of $46.18 billion for the quarter, compared to analyst estimates of $46.17 billion. During the same quarter in the prior year, the business posted $1.64 EPS. The firm’s revenue was up 3.5% compared to the same quarter last year. analysts expect that CVS Health Corp will post 5.88 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, February 2nd. Investors of record on Wednesday, January 24th were issued a $0.50 dividend. The ex-dividend date was Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.69%. CVS Health’s dividend payout ratio is presently 41.32%.

A number of analysts have commented on the stock. Loop Capital cut their price target on shares of CVS Health from $83.00 to $73.00 and set a “hold” rating on the stock in a research report on Tuesday, November 7th. Morgan Stanley raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price target on the stock in a research report on Friday, January 5th. Needham & Company LLC increased their price objective on shares of CVS Health from $85.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, January 2nd. SunTrust Banks increased their price objective on shares of CVS Health to $90.00 and gave the stock a “buy” rating in a research report on Friday, January 5th. Finally, Mizuho set a $95.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $88.27.

In related news, EVP Lisa Bisaccia sold 29,445 shares of the company’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total value of $2,208,375.00. Following the sale, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.61% of the company’s stock.

WARNING: This report was posted by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/02/08/cvs-health-corp-cvs-shares-sold-by-oppenheimer-asset-management-inc.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.